## First-Line Treatment of Acute Mania **Key Point:** Lithium carbonate remains the gold standard and first-line agent for acute mania in bipolar disorder I, with the strongest evidence base and longest clinical track record. ### Why Lithium is Preferred **High-Yield:** Lithium has: - Rapid onset of action in acute mania (5–7 days) - Proven efficacy in 60–70% of acute manic episodes - Unique anti-suicidal properties in bipolar disorder - Neuroprotective effects and long-term mood stabilization - Most robust evidence from RCTs and decades of clinical use ### Mechanism of Action - Inhibits inositol monophosphatase (affecting phosphatidylinositol signalling) - Increases GABA and serotonin neurotransmission - Reduces protein kinase C activity - Modulates GSK-3β (glycogen synthase kinase-3 beta) ### Therapeutic Considerations | Feature | Lithium | Valproate | Lamotrigine | Carbamazepine | |---------|---------|-----------|-------------|---------------| | **Onset (acute mania)** | 5–7 days | 3–5 days | Slow (weeks) | 5–7 days | | **Efficacy in mania** | 60–70% | 50–60% | Poor | 50–60% | | **Efficacy in depression** | Excellent | Moderate | Excellent | Moderate | | **First-line status** | Yes | Alternative | No | Alternative | | **Monitoring** | TDM, renal, thyroid | LFTs, CBC | Rash risk | Drug interactions | **Clinical Pearl:** Although valproate has a slightly faster onset, lithium remains first-line because of superior long-term outcomes, anti-suicidal effects, and the strongest guideline support (NICE, APA, Indian Psychiatric Society). **Mnemonic:** **LITHIUM FIRST** — Longest evidence, Ideal for both poles, Therapeutic drug monitoring, Highest efficacy, Ideal anti-suicide, Unique neuroprotection, Maintenance gold standard. [cite:Harrison 21e Ch 470]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.